Short Bowel Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Short Bowel Syndrome Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Short Bowel Syndrome Research. Learn more about our innovative pipeline today! @ Short Bowel Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Short Bowel Syndrome Pipeline Report

* On 22 August 2025, Hanmi Pharmaceutical Company Limited conducted a Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912 (sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF). The study consists of a screening period, a run-in period, a 6-months core treatment period, a 7-months extension treatment period and a 1-month safety follow-up period.
* DelveInsight's Short Bowel Syndrome pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Short Bowel Syndrome treatment.
* The leading Short Bowel Syndrome Companies such as VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics and others.
* Promising Short Bowel Syndrome Pipeline Therapies such as PJ009, Apraglutide, Teduglutide, Glepaglutide, Teduglutide 0.05mg/kg, Pancreatic Enzyme, HM15912, ZP1848, FE203799, and others.

Stay informed about the cutting-edge advancements in Short Bowel Syndrome treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Short Bowel Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Short Bowel Syndrome Emerging Drugs Profile

* Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome.

The Short Bowel Syndrome Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Short Bowel Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.
* Short Bowel Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Short Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Short Bowel Syndrome market.

Learn more about Short Bowel Syndrome Drugs opportunities in our groundbreaking Short Bowel Syndrome research and development projects @ Short Bowel Syndrome Unmet Needs [https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Short Bowel Syndrome Companies

VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics and others.

Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous

Short Bowel Syndrome Products have been categorized under various Molecule types such as

* Peptide
* Protein
* Propylene glycols
* Cell Therapy

Discover the latest advancements in Short Bowel Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Short Bowel Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Short Bowel Syndrome Pipeline Report

* Coverage- Global
* Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics and others.
* Short Bowel Syndrome Pipeline Therapies- PJ009, Apraglutide, Teduglutide, Glepaglutide, Teduglutide 0.05mg/kg, Pancreatic Enzyme, HM15912, ZP1848, FE203799, and others.
* Short Bowel Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Short Bowel Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Short Bowel Syndrome Pipeline on our website @ Short Bowel Syndrome Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Short Bowel Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Short Bowel Syndrome - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Glepaglutide: Zealand Pharma
* Mid Stage Products (Phase II)
* HM 15912: Hanmi Pharmaceutical
* Mid Stage Products (Phase II)
* Vurolenatide: 9 Meters Biopharma
* Early Stage Products (Phase I)
* SEFA-6179: NorthSea Therapeutics
* Preclinical and Discovery Stage Products
* GLP2-ELP: PhaseBio Pharmaceuticals
* Inactive Products
* Short Bowel Syndrome Key Companies
* Short Bowel Syndrome Key Products
* Short Bowel Syndrome- Unmet Needs
* Short Bowel Syndrome- Market Drivers and Barriers
* Short Bowel Syndrome- Future Perspectives and Conclusion
* Short Bowel Syndrome Analyst Views
* Short Bowel Syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=short-bowel-syndrome-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.